
"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at abiraterone with one of 2 new drugs for prostate cancer that has spread and is not responding to hormone therapy. The new drugs are called BEZ235 and BKM120.
If prostate cancer spreads to other parts of the body, doctors often treat it with hormone therapy. But after a while, this can stop working. If this happens, you may have a drug called abiraterone. But prostate cancer may get worse despite having abiraterone. In this trial, researchers are looking at 2 drugs called BEZ235 and BKM120. They want to find out if having one of these drugs alongside abiraterone helps men in this situation.
BKM120 is a type of biological therapy that bocks the activity of a group of proteins called PI3K. BEZ235 is another biological therapy drug that blocks the activity of both PI3K and a protein called mTOR. Both PI3K and mTOR are involved in cell growth. Blocking them may help stop cancer cells growing.
The aims of the trial are to
You may be able to enter this trial if you
As well as the above, to join the 2nd part of the trial
You cannot enter this trial if you
This phase 1 trial will recruit up to 130 men in different countries. The trial is in 2 parts. In the 1st part, the researchers are trying to find the highest doses of BEZ235 or BKM120 that you can have safely with abiraterone. Everybody taking part has abiraterone. The other drug you have will depend on when you join the trial.
The first few patients taking part will have a low dose of either BEZ235 or BKM120. If they don’t have any serious side effects, the next patients will have a higher dose. And so on, until they find the best doses to give. This is called a dose escalation study.
If you have BEZ235, you take it twice a day. If you have BKM120, you have it once a day. And you take abiraterone once a day.
As well as taking abiraterone and 1 of the trial drugs, you also take a steroid called prednisolone to help reduce some of the side effects. You take all the drugs by mouth. The trial team will tell you exactly how and when to take them.
In the 2nd part of the trial, researchers will compare the 2 drug combinations. They want to learn more about the side effects and whether the treatment helps men with advanced prostate cancer.
This part of the trial is randomised. The men taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.
Half the men have abiraterone and the highest safe dose of BKM120 found in part 1. The other half have abiraterone and the highest safe dose of BEZ235.
Whichever part of the trial you join, you can carry on having the trial treatment as long as your cancer doesn’t get worse and you don’t have bad side effects.
The trial team will ask you to fill out questionnaires before you start treatment, every 2 weeks for the first 3 months and then every month after that. The questionnaires will ask about how you’re feeling (your mood) including whether you are anxious or depressed.
People joining the 2nd part of the trial will also be asked to keep a diary to note down if they have any pain and details of any painkillers they take.
You see the trial team and have some tests before you start treatment. The tests include
If you have any cancer on your skin, your trial doctor may take a photograph. This will only show the cancer and the surrounding area. Your face will not be in the photograph and it will not be possible to identify you.
The trial team will try to get a sample of tissue removed when you had surgery or a in the past. If there is not a sample available, they may ask you to have a biopsy at this point.
You go to hospital
Each visit will last a few hours. At some visits, you may need to stay in hospital overnight.
You have regular blood tests and heart traces. You also have a heart scan and a CT or MRI scan every 3 months.
When you finish the treatment, you see the trial team again within the next 2 weeks. You have a physical examination, blood tests, a heart trace and a heart scan. You also have a CT or MRI scan if you haven’t had one recently. If you have any abnormal blood test results, the trial team may ask to see you again a couple of weeks later.
If you stop the treatment because your cancer gets worse, a member of the trial team will contact you by phone every 3 months to see how you are.
If you stop the treatment for any reason other than your cancer getting worse, you will see the trial team every 3 months until your cancer does start to get worse.
As this is the first time BKM120 and BEZ235 are being tested alongside abiraterone, there may be side effects we don’t know about yet.
In other trials, the most common side effects of BKM120 have been
The most common side effects of BEZ235 have been
We have more information about the side effects of abiraterone and prednisolone in our cancer drugs section.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann de Bono
Experimental Cancer Medicine Centre (ECMC)
Novartis
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”